In particular, GBP2 completely inhibited the MCL-1-mediated promotion of the survival of CML cells through competitive inhibition, resulting in BAK liberation from MCL-1. This evidence concerns the gene MCL1 and chronic myelogenous leukemia, BCR-ABL1 positive.